Cijauskaite Elena, Kazenaite Edita, Strainiene Sandra, Sadauskaite Goda, Kurlinkus Benediktas
Faculty of Medicine, Vilnius University, Vilnius 01513, Lithuania.
Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius 01513, Lithuania.
World J Clin Cases. 2023 Jun 26;11(18):4350-4359. doi: 10.12998/wjcc.v11.i18.4350.
Immune checkpoint inhibitors are one of the modern treatment methods for advanced malignancies. However, this group of medications is also associated with various immune-related adverse events, such as colitis or pneumonitis. Immune checkpoint inhibitor-induced gastritis is a less common adverse event.
We describe a 64-year-old woman presenting with diarrhea, nausea, and discomfort in the upper abdominal region. The patient had a history of metastatic lung cancer, which was treated with nivolumab. During the first endoscopy, an infiltrating gastric tumour was suspected. Later, based on endoscopic, histological and radiological findings, nivolumab-induced gastritis was diagnosed. The patient was successfully treated with three courses of omeprazole.
As a consequence of the increased use of immune checkpoint inhibitors, a growing number of reported immune-related adverse events could be expected. The diagnosis of immune checkpoint inhibitor-induced gastritis should be considered when assessing a patient treated with nivolumab with upper gastrointestinal distress.
免疫检查点抑制剂是晚期恶性肿瘤的现代治疗方法之一。然而，这类药物也与各种免疫相关不良事件有关，如结肠炎或肺炎。免疫检查点抑制剂诱发的胃炎是一种较罕见的不良事件。
我们描述了一名64岁女性，出现腹泻、恶心和上腹部不适。该患者有转移性肺癌病史，曾接受纳武单抗治疗。在首次内镜检查时，怀疑有浸润性胃肿瘤。后来，根据内镜、组织学和影像学检查结果，诊断为纳武单抗诱发的胃炎。该患者通过三个疗程的奥美拉唑治疗成功治愈。
由于免疫检查点抑制剂使用的增加，预计会有越来越多的免疫相关不良事件被报道。在用纳武单抗治疗且有上消化道不适的患者进行评估时，应考虑免疫检查点抑制剂诱发胃炎的诊断。
